CGT CDMO Report: Market Outlook - Q3 2025
Cell and gene therapy is growing faster than it can be manufactured. This outlook maps the CDMO landscape behind that gap - who can actually make these therapies, what the technology and geopolitical shifts have done to the competitive order, and why the binding constraint has moved from capital and capacity to people.
What this report answers
- Which CDMOs can genuinely manufacture cell and gene therapies at commercial scale, and how do they differ?
- How fast is each segment of the CGT CDMO market growing, and where is the money going?
- What did the BIOSECURE Act actually do to the competitive map, rather than what it was meant to do?
- Why do bottlenecks persist when capacity keeps being announced?
- Which roles are the real rate limiter on a CGT facility running to schedule?
- What should a developer be diligencing in a manufacturing partner that it was not diligencing two years ago?
30,000 to 40,000
patients treated across all eight approved CAR-T products in seven years - the access gap the report uses to argue the bottleneck is manufacturing, not science.
4,000
roles the report cites as the forecast UK cell and gene therapy workforce shortfall by 2028, in its case that talent has replaced capital as the sector constraint.
What the analysis establishes
Market dynamics and segment sizing
The report sizes the CGT CDMO market segment by segment - viral vector, cell therapy services, ancillary QC and release testing, and enabling platforms - with 2025 estimates, 2030 projections and a growth rate for each, plus the geographic weighting behind them. It is explicit that these are aggregated third-party estimates rather than primary research, and says so on the page.
A directory of who can actually manufacture
Chapter 3 is a competitive assessment rather than a list. Every operator is placed in a tier and profiled on headquarters, hub locations, modality focus, capability set, whether it serves clinical or commercial phase, and its most consequential 2024-2025 strategic move. The tiering is the argument: it separates integrated global leaders from ascendant challengers, disruptors and regional specialists.
Consolidation, geopolitics and sovereign capacity
The outlook traces what the last eighteen months of M&A and restructuring did to the competitive hierarchy, including one restructuring it treats as a cautionary tale about expansion outrunning demand. It also works through how one piece of US legislation reshaped ownership of a major CGT platform, and reaches a conclusion about the outcome that is not the one the legislation intended.
The great bottleneck, deconstructed
Chapter 6 takes the manufacturing problem apart layer by layer: facility engineering and the cleanroom pressure paradox that multi-modal sites create, the viral vector quality and scalability problem, the autologous scale-out against allogeneic scale-up divide, and the cryogenic final mile. It closes with corporate case studies of launches and strategic reversals.
The human capital crisis
The report argues the constraint on growth is no longer capital. It identifies the specific technical disciplines whose scarcity idles facilities and delays clinical programmes, describes the leadership profile the sector cannot find enough of, and documents the migration pattern moving experienced operators out of the large CDMOs. Three anonymised case studies show what the gap costs when it goes unaddressed.
Strategic outlook and partner diligence
The closing chapter sets out how CDMO selection criteria have changed, covering financial backing, geopolitical exposure, platform fit and leadership stability. It then looks ahead to allogeneic, in-vivo and non-viral modalities and what those require of a manufacturing base, and ends with five questions it argues every CGT leadership team should be able to answer.
How it was built
Synthesised from public sources - company disclosures, regulatory filings, transaction announcements and published industry research - and organised into a structured competitive assessment. Market sizing is labelled in the document as aggregated third-party estimate rather than primary research. The competitive directory is described by the report as representative rather than exhaustive. The talent case studies are anonymised composites drawn from search work, presented as patterns rather than named events.
Written for CGT developer leadership teams, CDMO executives, investors underwriting advanced therapy manufacturing, and heads of technical operations choosing or reviewing a manufacturing partner.
Contents
- Executive Summary: A Market of Paradox and Opportunity
- Global Market Dynamics: The Forces Shaping the New Competitive Battleground
- Directory of Global CGT CDMOs and Enablers: A Competitive Assessment
- Strategic Archetypes: The Business Models Shaping CGT Manufacturing
- The CGT Manufacturing Value Chain: A Segment-by-Segment Analysis
- The Great Bottleneck: Deconstructing the Barriers to Scale
- The Human Capital Crisis: Leadership and Hiring Trends in CGT
- Strategic Outlook and Forward-Looking Analysis
Organisations covered
Lonza, Catalent, Thermo Fisher Scientific, Minaris Advanced Therapies, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Charles River Laboratories, Samsung Biologics, Sartorius, Cellares, Resilience, RoslinCT, Forge Biologics, Ajinomoto, Univercells Group, WuXi Advanced Therapies, Altaris, Novo Holdings, Miltenyi Biotec, Ori Biotech, Andelyn Biosciences, Genezen, Kincell Bio, ElevateBio, Danaher
The full 29-page briefing is free. Tell us where to send it and it downloads immediately.
Weaponised Capacity: The CDMO Report 2026
This outlook maps the CGT manufacturing base as it stood in Q3 2025. The flagship CDMO report takes the analysis across the whole contract manufacturing sector and forward to 2026.
See the full report →